Higher blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations correlate with lower olfactory scores in essential tremor

NeuroToxicology

Volumn 29, Issue 3, 2008, Pages 460-465

  Louis, Elan D ^a,b,c   Rios, Eileen ^a   Pellegrino, Kathryn M ^a   Jiang, Wendy ^d   Factor Litvak, Pam ^c   Zheng, Wei ^d  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Purdue University School of Health Sciences ^*  (United States)

^c NONE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Carboline alkaloid; Cerebellum; Epidemiology; Essential tremor; Harmane; Olfaction

Indexed keywords

HARMAN; NEUROTOXIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEREBELLUM; CEREBELLUM DISEASE; CONTROLLED STUDY; ESSENTIAL TREMOR; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; SCORING SYSTEM; SMELLING;

AGED; CEREBELLAR DISEASES; COGNITION DISORDERS; ESSENTIAL TREMOR; FEMALE; HARMINE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEUROTOXINS; PSYCHOMOTOR PERFORMANCE; SMELL;

EID: 44649145107     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2008.02.013     Document Type: Article

References (53)

1. Anderson N.J., Tyacke R.J., Husbands S.M., Nutt D.J., Hudson A.L., and Robinson E.S. In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology 50 (2006) 269-276
2. Applegate L.M., and Louis E.D. Essential tremor: mild olfactory dysfunction in a cerebellar disorder. Parkinsonism Relat Disord 11 (2005) 399-402
3. Benito-Leon J., Bermejo-Pareja F., Morales J.M., Vega S., and Molina J.A. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 18 (2003) 389-394
4. Benito-Leon J., Louis E.D., and Bermejo-Pareja F. Population-based case-control study of cognitive function in essential tremor. Neurology 66 (2006) 69-74
5. Brandt J.S.M., and Folstein M. The telephone interview for cognitive status. Neuropsychiatr Neuropsychol Beh Neurol (1988) 1
6. Bucher S.F., Seelos K.C., Dodel R.C., Reiser M., and Oertel W.H. Activation mapping in essential tremor with functional magnetic resonance imaging. Ann Neurol 41 (1997) 32-40
7. Connelly T., Farmer J.M., Lynch D.R., and Doty R.L. Olfactory dysfunction in degenerative ataxias. J Neurol Neurosurg Psychiatry 74 (2003) 1435-1437
8. Deiss V., and Baudoin C. Hyposmia for butanol and vanillin in mutant staggerer male mice. Physiol Behav 61 (1997) 209-213
9. Deiss V., and Baudoin C. Olfactory learning abilities in staggerer mutant mice. C R Acad Sci III 322 (1999) 467-471
10. Dogu O., Sevim S., Camdeviren H., Sasmaz T., Bugdayci R., Aral M., et al. Prevalence of essential tremor: door-to-door neurologic exams in Mersin Province. Turkey Neurol 61 (2003) 1804-1806
11. Doty R.L., Deems D.A., and Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38 (1988) 1237-1244
12. Doty R.L., Reyes P.F., and Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 18 (1987) 597-600
13. Doty R.L., Stern M.B., Pfeiffer C., Gollomp S.M., and Hurtig H.I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992) 138-142
14. Du W., Aloyo V.J., and Harvey J.A. Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. Brain Res 770 (1997) 26-29
15. Fabrizio E., Vanacore N., Valente M., Rubino A., and Meco G. High prevalence of extrapyramidal signs and symptoms in a group of Italian dental technicians. BMC Neurol 7 (2007) 24
16. Ferdon S., and Murphy C. The cerebellum and olfaction in the aging brain: a functional magnetic resonance imaging study. Neuroimage 20 (2003) 12-21
17. Frye R.E., Schwartz B.S., and Doty R.L. Dose-related effects of cigarette smoking on olfactory function. JAMA 263 (1990) 1233-1236
18. Guan Y., Louis E.D., and Zheng W. Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats. J Toxicol Environ Health A 64 (2001) 645-660
19. Herraiz T. Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Addit Contam 21 (2004) 1041-1050
20. Jenkins I.H., Bain P.G., Colebatch J.G., Thompson P.D., Findley L.J., Frackowiak R.S., et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol 34 (1993) 82-90
21. Jiménez-Jiménez F.J., de Toledo-Heras M., Alonso-Navarro H., Ayuso-Peralta L., Arévalo-Serrano J., Ballesteros-Barranco A., et al. Environmental risk factors for essential tremor. Eur Neurol 58 (2007) 106-113
22. Linn B.S., Linn M.W., and Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 16 (1968) 622-626
23. Louis E.D., Bromley S.M., Jurewicz E.C., and Watner D. Olfactory dysfunction in essential tremor: a deficit unrelated to disease duration or severity. Neurology 59 (2002) 1631-1633
24. Louis E.D., Faust P.L., Vonsattel J.P., Honig L.S., Rajput A., Robinson C.A., et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 130 (2007) 3297-3307
25. Louis E.D., Ford B., Lee H., and Andrews H. Does a screening questionnaire for essential tremor agree with the physician's examination?. Neurology 50 (1998) 1351-1357
26. Louis E.D., and Jurewicz E.C. Olfaction in essential tremor patients with and without isolated rest tremor. Mov Disord 18 (2003) 1387-1389
27. Louis E.D., and Ottman R. How familial is familial tremor? The genetic epidemiology of essential tremor. Neurology 46 (1996) 1200-1205
28. Louis E.D., Ottman R., Ford B., Pullman S., Martinez M., Fahn S., et al. The Washington heights-inwood genetic study of essential tremor: methodologic issues in essential-tremor research. Neuroepidemiology 16 (1997) 124-133
29. Louis E.D., Ottman R., and Hauser W.A. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. Mov Disord 13 (1998) 5-10
30. Louis E.D., Vonsattel J.P., Honig L.S., Lawton A., Moskowitz C., Ford B., et al. Essential tremor associated with pathologic changes in the cerebellum. Arch Neurol 63 (2006) 1189-1193
31. Louis E.D., Zheng W., Applegate L., Shi L., and Factor-Litvak P. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology 65 (2005) 391-396
32. Louis E.D., Zheng W., Jurewicz E.C., Watner D., Chen J., Factor-Litvak P., et al. Elevation of blood beta-carboline alkaloids in essential tremor. Neurology 59 (2002) 1940-1944
33. Louis E.D., Zheng W., Mao X., and Shungu D.C. Blood harmane is correlated with cerebellar metabolism in essential tremor: a pilot study. Neurology 69 (2007) 515-520
34. Louis E.D., Jiang W., Pellegrino K.M., Rios E., Factor-Litvak P., Henchcliffe C., et al. Elevated blood harmane (1-methyl-9h-pyrido[34-b]indole) concentrations in essential tremor. Neurotoxicology 29 (2008) 294-300
35. Mainland J.D., Johnson B.N., Khan R., Ivry R.B., and Sobel N. Olfactory impairments in patients with unilateral cerebellar lesions are selective to inputs from the contralesional nostril. J Neurosci 25 (2005) 6362-6371
36. Martin F.C., Thu Le A., and Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord 20 (2005) 298-305
37. McKenna D.J. Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res 73 (1996) 109-116
38. Milner T.E., Cadoret G., Lessard L., and Smith A.M. EMG analysis of harmaline-induced tremor in normal and three strains of mutant mice with Purkinje cell degeneration and the role of the inferior olive. J Neurophysiol 73 (1995) 2568-2577
39. O'Hearn E., and Molliver M.E. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci 17 (1997) 8828-8841
40. Pagan F.L., Butman J.A., Dambrosia J.M., and Hallett M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology 60 (2003) 1344-1347
41. Pfau W., and Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B: Anal Technol Biomed Life Sci 802 (2004) 115-126
42. Qureshy A., Kawashima R., Imran M.B., Sugiura M., Goto R., Okada K., et al. Functional mapping of human brain in olfactory processing: a PET study. J Neurophysiol 84 (2000) 1656-1666
43. Rommelspacher H., Schmidt L.G., and May T. Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res 15 (1991) 553-559
44. Salemi G., Aridon P., Calagna G., Monte M., and Savettieri G. Population-based case-control study of essential tremor. Ital J Neurol Sci 19 (1998) 301-305
45. Shill H.A.C., Sabbagh M., Connor D., Caviness J., and Beach T. Pathological changes in prospectively-ascertained essential tremor subjects. Neurology (2007) 68
46. Singer C., Sanchez-Ramos J., and Weiner W.J. Gait abnormality in essential tremor. Mov Disord 9 (1994) 193-196
47. Sobel N., Prabhakaran V., Hartley C.A., Desmond J.E., Zhao Z., Glover G.H., et al. Odorant-induced and sniff-induced activation in the cerebellum of the human. J Neurosci 18 (1998) 8990-9001
48. Tucker B. Report of a case of tumor of the ponto-cerebellar angle on the left side of the brain with bilateral loss of smell and disturbance of taste. Old Dominion J Med Surg 13 (1911) 327-334
49. Velazquez-Perez L., Fernandez-Ruiz J., Diaz R., Gonzalez R.P., Ochoa N.C., Cruz G.S., et al. Spinocerebellar ataxia type 2 olfactory impairment shows a pattern similar to other major neurodegenerative diseases. J Neurol 253 (2006) 1165-1169
50. Yousem D.M., Williams S.C., Howard R.O., Andrew C., Simmons A., Allin M., et al. Functional MR imaging during odor stimulation: preliminary data. Radiology 204 (1997) 833-838
51. Zesiewicz T.A., Elble R., Louis E.D., Hauser R.A., Sullivan K.L., Dewey Jr. R.B., et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 64 (2005) 2008-2020
52. Zetler G., Singbartl G., and Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology 7 (1972) 237-248
53. Zheng W., Wang S., Barnes L.F., Guan Y., and Louis E.D. Determination of harmane and harmine in human blood using reversed-phased high-performance liquid chromatography and fluorescence detection. Anal Biochem 279 (2000) 125-129